News from Monday, June 2, 2025
Articles
Novel Algorithm Boosts Stroke Triage, Outcomes Across the United States
(6/2, Sue Hughes, Medscape) reports “...Results also showed that the new algorithm provided especially strong benefits for patients with LVO stroke in rural areas, reducing time to EVT by an average of 166 minutes compared with guideline-based transport and by 181 minutes compared with going to the nearest facility. This led to a 7.8% increase in the number of rural patients achieving a good neurologic outcome.” Full
Computable Operational Definitions in the Real-World – Improving the Accuracy of Patient Identification in RWD Studies for Cervical and Uterine Cancers
(6/2, The Evidence Base) reports “In part two of our interview series on computable operational definitions (CODefs), Evelyn Rizzo (Founder & Principal HEOR Consultant, Mobility HEOR) and Aaron Kamauu (CEO, Navidence) discuss the research, ‘Operational Definitions in Practice: Finding and Evaluating Algorithms for Identifying Patients with Cervical and Uterine Cancer for Real World Data Studies,’ recently presented at ISPOR 2025.” Full
Managed Care Reflections: A Q&A With Melinda B. Buntin, PhD
(6/2, Melinda B. Buntin, PhD, Christina Mattina, The American Journal of Managed Care) reports “...[Buntin:] I think we’re at a very critical inflection point right now because a lot of the formal evaluations of value-based health care demonstrations, like those done by [CMMI], have come to the conclusion that those demonstrations saved a few percent on health care spend. But I would argue that they were comparing them [with] a control group, if you will, that wasn’t a true control group, because this value zeitgeist has really permeated the whole health care system, the whole health care industry, for arguably about 20 years now. And so the question is whether we’ll draw what I would argue is the wrong conclusion from these evaluations and think that value-based care wasn’t and isn’t important. If we do that and we pull back, then I think we will start to see health care spending growth increase.” Full
UK: NICE Recommends Mirikizumab for Crohn’s Disease Treatment
(6/2, John Pinching, PharmaTimes) reports “The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending mirikizumab (Omvoh) for adults with moderately to severely active Crohn’s disease who have not responded to previous biological treatment or cannot tolerate it.” Full
Press Releases
Dr. Julie Patterson Named a "40 Under 40 in Cancer" Awardee
(5/30, National Pharmaceutical Council Press Release) “...‘Dr. Patterson's work exploring the impact of the IRA on people living with cancer not only captured what the expected unintended consequences would be, she is now generating research and evidence on the early signals that are actually being observed,’ said John O'Brien, NPC President and CEO...‘Cancer is personal to me and my family. I've seen first-hand what advances in science can do for people living with cancer and their families," said Dr. Patterson. ‘High-quality research and evidence can help decision-makers understand the unintended consequences of policies and help more people impacted by cancer get more time with their loved ones. I'm grateful to the '40 Under 40 in Cancer' award initiative for this recognition — and there is more work to be done.’” Full
CHLA-Led Behavioral Health Team Receives $6.4 Million Research Grant for Clinical Trial on Combined Treatments for Pediatric Anxiety
(6/2, Children's Hospital Los Angeles Press Release) Anxiety in children and adolescents is a complex issue for which there are a variety of treatment options. Bradley Peterson, MD, Chief of Psychiatry and Co-Director of the Behavioral Health Institute at Children’s Hospital Los Angeles, researches brain-based childhood psychiatric disorders like anxiety, and investigates how different treatments can be combined to more effectively address these disorders. To support his team’s newest research in this area, the Patient-Centered Outcomes Research Institute (PCORI)- Opens in a new window has awarded Dr. Peterson a $6.4 million grant.” Full
Advancing Personalized Medicine Through Pharmacogenomics: Insights from Ochsner Health
(6/2, Ochsner Health Press Release) “...‘Pharmacogenomics embodies a new frontier in precision medicine, enabling us to fine-tune treatments to the genetic profiles of individual patients,’ says Dr. Catherine Oliver, PharmD, BCPS, DPLA, CPGx, and lead author of the study. ‘Our implementation journey at Ochsner Health underscores the pivotal role pharmacists play in spearheading these personalized healthcare innovations.’” Full
Journals
An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists
Sourbha S Dani, et al.
May 2025, JACC Advances
Comparative Effectiveness of Inhaled Fluticasone Propionate/Salmeterol and Budesonide/Formoterol Fixed-Dose Combinations in Asthma Control - A Retrospective United States Database Analysis
Nicola A Hanania, et al.
May 28, 2025, Respiratory Medicine
Comparative Effectiveness of Alternative Second-Line Oral Glucose-Lowering Therapies for Type 2 Diabetes: A Precision Medicine Approach Applied to Routine Data
Stephen O'Neill, et al.
May 31, 2025, Diabetologia
Comparative Effectiveness of Natalizumab and Anti-CD20 Monoclonal Antibodies in Relapsing-Remitting Multiple Sclerosis: A Real-World Propensity-Score Matched Study
Bassem Yamout, et al.
June 1, 2025, Journal Neurology, Neurosurgery and Psychiatry